Cargando…

Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing

BACKGROUND/AIMS: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge. METHODS: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeon, Min Ji, Yu, Eun Sang, Choi, Chul Won, Kim, Dae Sik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636549/ https://www.ncbi.nlm.nih.gov/pubmed/37599392 http://dx.doi.org/10.3904/kjim.2023.134

Ejemplares similares

Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
por: Jeon, Youngwoo
Publicado: (2023)

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
por: Mondello, Patrizia, et al.
Publicado: (2014)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas
por: Paik, Jin Ho, et al.
Publicado: (2014)

Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
por: Choi, Yong Won, et al.
Publicado: (2014)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022)

P1173: CLINICAL APPLICABILITY OF TARGETED NEXT-GENERATION SEQUENCING FOR PRECISION MEDICINE IN DIFFUSE LARGE B CELL LYMPHOMA
por: Huang, D., et al.
Publicado: (2022)

Next-Generation Sequencing Highlights of Diffuse Large B-cell Lymphoma in a Tertiary Care Hospital in North India
por: Mamgain, Garima, et al.
Publicado: (2022)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?
por: Park, Sang-Gon
Publicado: (2019)

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis
por: Zhou, Xuan, et al.
Publicado: (2017)

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
por: Ko Ko, Nway Le, et al.
Publicado: (2020)

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
por: Gutierrez, Antonio, et al.
Publicado: (2020)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
por: Haujir, A., et al.
Publicado: (2022)

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
por: Kim, Yu Ri, et al.
Publicado: (2023)

Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses
por: Todorovic Balint, Milena, et al.
Publicado: (2016)

Overcoming bias and systematic errors in next generation sequencing data
por: Taub, Margaret A, et al.
Publicado: (2010)

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing
por: Gao, Fan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8va7cglsk9s4o9b1ctkv63jld9